Orthocell Ltd (ASX:OCC, OTC:ORHHF) closed the September quarter with revenue of A$3.6 million and continued growth in sales of its flagship nerve repair product, Remplir, supported by accelerating US adoption and expansion into new international markets. US Remplir unit sales rose 25% quarter-on-quarter to 149 units, driving a 20% increase in global Remplir revenue, which now accounts for more ...
Regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) will host an investor webinar on Thursday, October 22, 2026, providing an update on its September quarter results, the US rollout of Remplir and other strategic initiatives. The webinar will follow the release of Orthocell's quarterly results for the period ended September 30, 2026, and will give investors an overview of the compa...
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported encouraging early clinical results for its Remplir™ nerve repair technology in prostate cancer surgery, with 80% of patients demonstrating positive urinary continence outcomes and 75% of eligible patients showing a return of erectile function. The findings from an initial five-patient case series involving advanced prostate cancer patients support...
CHICAGO--(BUSINESS WIRE)--OCC today announced it will provide CCP and settlement services for IEX Options LLC, a new options exchange from Investors' Exchange LLC.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has recorded the first commercial sales of its Remplir™ nerve repair product in Thailand, extending the regenerative medicine company's Asian footprint and opening another revenue-generating market for the product. The first sales follow Thai FDA approval and the appointment of MediTime as Orthocell's exclusive in-country distributor, giving the company an est...
CHICAGO--(BUSINESS WIRE)--OCC today announced it will provide central counterparty clearing and settlement services for MX2 Options, a new options exchange from MEMX Group.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.